Strongbridge Biopharma plc Expands Commercial Capabilities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires

DUBLIN, Ireland and TREVOSE, Pa., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the expansion of its rare disease commercial capabilities with the hiring of Dave Bonnell, senior vice president of sales and marketing, and Scott Wilhoit, senior vice president, global market access and patient services.  

“We are excited to welcome both Dave and Scott to the Strongbridge team at such a transformative time for the Company,” said Matthew Pauls, president and chief executive officer of Strongbridge. “In these new senior leadership positions, Dave will be responsible for sales and marketing efforts, including the construction of an experienced rare disease sales force, and Scott will lead all aspects of market access, including reimbursement and patient services. Their collective industry expertise in rare diseases, along with their passion and proven success in launching orphan therapies, will be invaluable as Strongbridge prepares to launch its first product, KEVEYIS® (dichlorphenamide), in the U.S. market this year.”

Dave has more than 25 years of commercial experience within the biopharmaceutical industry. Before joining Strongbridge, he served as vice president, rare disease and GI specialty sales at Shire Pharmaceuticals, where he directed multiple highly-specialized sales teams, focused on two rare diseases: hypoparathyroidism and short bowel syndrome. Prior, Dave served as vice president, neuroscience sales at Shire, where he successfully led the ADHD sales organization. In addition, Dave served in a variety of sales and marketing leadership positions at AstraZeneca and holds a B.S. in business administration from Central Michigan University.

Scott brings nearly 30 years of industry experience, most of which has been focused within market and patient access in the rare disease category. He most recently served as vice president, market and patient access at Marathon Pharmaceuticals, where he designed and developed the access strategy, including a comprehensive patient services and distribution model. Previously, he served as vice president, market access and health services at PTC Therapeutics, leading the pre-launch market access strategy and tactical planning efforts for the company’s Duchenne Muscular Dystrophy treatment. In addition, Scott served as vice president, pricing, access and patient services at NPS Pharmaceuticals Inc., where he was responsible for market access readiness planning and execution for the company’s first commercial product, and led the global effort to develop commercial pricing, distribution network, and core patient services strategies for the company’s second rare disease product. Scott has also served in a variety of positions with increasing responsibility at Clarus Therapeutics, Auxilium Pharmaceuticals, Biovail Corporation and Johnson & Johnson. Scott served as a Field Artillery Officer in the U.S. Army and holds a B.S. in criminology from Missouri Western State University.

About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com .

ABOUT KEVEYIS

KEVEYIS ® Indication KEVEYIS ®  (dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

KEVEYIS Important Safety Information In clinical studies, the most common side effects of KEVEYIS were a numbness or tingling, difficulty thinking and paying attention, changes in taste, and confusion. These are not all of the possible side effects that you may experience with KEVEYIS. Talk to your doctor if you have any symptoms that bother you or do not go away.

KEVEYIS is not for everyone. Do not take KEVEYIS if you:

  • Are on a high-dose aspirin regimen
  • Are allergic to sulfa-based drugs
  • Have liver, kidney, or certain lung conditions
  • Are pregnant, planning to become pregnant, or nursing
  • Are under 18 years old

Taking KEVEYIS may cause a drop in the amount of potassium (an electrolyte) in your body, which can lead to heart problems. Ask your doctor if you need to eat foods that contain high amounts of potassium while taking KEVEYIS.

Your body may produce too much acid or may not be able to remove enough acid from body fluids while taking KEVEYIS. Your doctor will run tests on a regular basis to check for signs of acid buildup and may reduce your dose or stop your treatment with KEVEYIS.

KEVEYIS may also increase the risk of falls, especially in elderly patients and patients taking high doses of KEVEYIS. Use caution when driving, operating machinery, or performing any other hazardous activities while taking KEVEYIS, as this medication may cause drowsiness.

You are encouraged to report side effects to Strongbridge Biopharma at 1-855-324-8912, or to the FDA at 1-800-FDA-1088 or visit  www.fda.gov/medwatch/ . For more information, go to  www.keveyis.com .

For additional KEVEYIS important safety information, please see full prescribing information at www.keveyis.com .

STRONGBRIDGE BIOPHARMA™ is a trademark of Strongbridge Biopharma plc. 


KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, contained in this press release, are forward-looking statements. These statements relate to future events and involve known and unknown risks, including, without limitation, uncertainties regarding Strongbridge's strategy, plans, and objectives of management for future operations. The words "anticipate," "estimate," "expect," "intend," "may," "plan," "potential," "project," "target," "will," "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.

Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 mnanus@troutgroup.com USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Joseph Margolis Shows Strong Faith in Extra Space Storage

Updated Category News Views 133

Joseph Margolis Shows Strong Faith in Extra Space Storage Recently, a significant insider purchase was conducted by Joseph Margolis, who holds the position of Chief Executive Officer at Extra Space Storage (EXR). According to the latest SEC filing, Margolis acquired 27,741 shares of the company, amounting to a considerable investment of $4,232,166. The market had a...

Continue Reading
Investigation Into Arcadium Lithium Sale Sparks Concerns

Updated Category News Views 192

Investigation Launched into Arcadium Lithium Shareholder Rights The former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., is leading an inquiry regarding an important corporate transaction involving Arcadium Lithium plc (NYSE: ALTM). This investigation, undertaken by the law firm Kahn Swick & Foti, LLC, seeks to assess whether the terms of the proposed sale to...

Continue Reading
Actian Introduces Advanced Federated Data Catalog for Businesses

Updated Category News Views 148

Actian Launches Innovative Federated Data Catalog Actian, the data and analytics division of HCLSoftware, is setting new standards in data management with the introduction of the Actian Zeenea Federated Data Catalog. This advanced platform simplifies data discovery, empowering users across enterprises to harness valuable data resources effectively. With the acquisition of...

Continue Reading
Oil-Dri Corporation Reports Impressive Second Quarter Growth

Updated Category News Views 123

Oil-Dri Corporation Achieves Significant Growth Oil-Dri Corporation of America (NYSE: ODC), a reputable name in the production and marketing of sorbent mineral products, has shared its impressive financial performance for the second quarter of fiscal 2025, marking substantial growth for the company. Financial Highlights of the Second Quarter During this reporting period,...

Continue Reading
Power Metallic: Drill Assays Fuel Growth Optimism at Lion

Updated Category News Views 34

Striking Copper: Panning Out or Fools' Gold? Well, here's a dose of copper digging straight from the heart of the Lion Zone with Power Metallic Mines (TSXV: PNPN, OTCBB: PNPNF) at the helm. Now, if copper's your game, the latest assay results might just tickle your fancy. We're talking hefty 13.30 meters at 3.98% CuEqRec in hole 26-115 and, get this, a juicy 5.26 meters...

Continue Reading